ANI Pharmaceuticals宣布要约收购 Egetis Therapeutics，扩大其罕见病业务的范围与规模-动脉网

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

GlobeNewswire 等信源发布 2026-11-05 06:33



可切换为仅中文







Egetis Therapeutics’ lead asset, EMCITATE

Egetis Therapeutics 的核心资产 EMCITATE

, is

，是

the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 in 70K males

美国及欧洲首个且唯一获批用于治疗与MCT8缺乏症（一种罕见的遗传性疾病，约影响七万分之一男性）相关的外周性甲状腺毒症的治疗方案

Supported by ANI’s proven track record in Rare Disease, EMCITATE

依托 ANI 在罕见病领域经证实的卓越业绩，EMCITATE

has potential to reach over $300 million in peak sales in its approved indication, with U.S. and EU Orphan Drug Exclusivity and patent protection into 2045

在其获批适应症中，峰值销售额有望超过3亿美元，并享有美国及欧盟的孤儿药独占权以及直至2045年的专利保护。

Combines ANI’s resources, Rare Disease expertise, and infrastructure with Egetis’

将ANI的资源、罕见病专业知识和基础设施与Egetis相结合

commercialization

商业化

and clinical development capabilities

以及临床开发能力

The Offer reflects a purchase price of SEK 11.25 per share representing a 27% premium to the 60-day VWAP of shares of Egetis and total value of approximately SEK 5.6 billion, or $560M

该要约的收购价格为每股11.25瑞典克朗，较Egetis股票60日成交量加权平均价（VWAP）溢价27%，总价值约为56亿瑞典克朗（约合5.6亿美元）。

U.S.; and an enterprise value of approximately $434

美国；企业价值约为434美元

million when adjusted for estimated proceeds of Egetis’ sale of its Rare Pediatric Disease Priority Review Voucher

在扣除Egetis出售其罕见儿科疾病优先审评券的预计收益后，为百万美元

The acquisition is unanimously recommended by Egetis’ Board, and supported by shareholders in Egetis controlling approximately 42 percent of the shares

Egetis 董事会一致推荐该项收购，并得到持有 Egetis 约 42% 股份的股东的支持。

ANI will release 3Q 2026 earnings results at 6:50 am ET and host conference call today at 8:00 am ET

ANI 将于美国东部时间上午 6:50 发布 2026 年第三季度财报，并于当天上午 8:00（美国东部时间）举行电话会议。

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).

新泽西州普林斯顿，2026年11月5日（环球电讯社）——ANI Pharmaceuticals, Inc.（纳斯达克股票代码：ANIP）（“ANI”或“公司”）宣布一项建议的公开要约，以收购Egetis Therapeutics AB (publ)（“Egetis”）（该“要约”）。

Egetis is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Egetis’ lead product, EMCITATE

Egetis 是一家处于商业化阶段的制药公司，专注于为存在重大未满足医疗需求的罕见病患者开发和提供创新疗法。Egetis 的核心产品 EMCITATE

, was approved by the European Commission on February 12, 2025, and by the U.S. Food and Drug Administration (FDA) on September 28, 2026, as the first and only approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency (Allan–Herndon–Dudley syndrome).

于2025年2月12日获得欧盟委员会批准，并于2026年9月28日获得美国食品药品监督管理局（FDA）批准，成为首个且唯一获批用于治疗MCT8缺乏症（Allan–Herndon–Dudley综合征）成人及儿科患者外周甲状腺毒症的药物。

“This proposed acquisition further accelerates our transformation with a substantial majority of our revenues expected to be derived from higher margin rare disease products by decade’s end and supports our mission of serving vulnerable patient populations with unmet medical needs,” said Nikhil Lalwani, President and Chief Executive Officer of ANI.

ANI 总裁兼首席执行官尼基尔·拉尔瓦尼表示：“此次拟议收购将进一步加速我们的转型，预计到本十年末，公司绝大部分收入将来自高利润率的罕见病产品，这也支持了我们服务于存在未满足医疗需求的弱势患者群体的使命。”

“We have followed the Egetis team closely, and we have been deeply impressed by their commitment to patients with MCT8 deficiency and to the families who care for them.”.

“我们密切关注了Egetis团队，他们对MCT8缺乏症患者的承诺以及对其护理家庭的承诺给我们留下了深刻的印象。”

Mr. Lalwani added, “The proposed transaction reflects the disciplined execution of the strategy we have consistently outlined: adding differentiated, durable commercial Rare Disease assets that leverage our existing expertise and infrastructure. The acquisition of Egetis would strengthen our Rare Disease portfolio and development capabilities.

拉尔瓦尼先生补充道：“拟议中的交易体现了我们一贯阐述的战略的审慎执行：增加差异化的、具有持久商业价值的罕见病资产，以利用我们现有的专业知识和基础设施。收购Egetis公司将增强我们的罕见病产品组合和研发能力。”

By leveraging our resources and the groundwork laid by Egetis, we estimate peak sales potential for EMCITATE.

通过利用我们的资源以及Egetis所奠定的基础，我们估算出EMCITATE的峰值销售潜力。

of over $300 million in its approved indication coupled with durable protection into 2045, bolstering our long-term growth and profitability profile. We believe that ANI is well-positioned to successfully bring EMCITATE

在其获批适应症中实现超过3亿美元的收入，并提供直至2045年的持久保护，从而增强我们的长期增长和盈利能力。我们相信，ANI处于有利地位，能够成功推出EMCITATE

to patients and caregivers.”

致患者和照护者。”

Strategic Rationale

战略理由

Advances ANI’s mission of “Serving Patients, Improving Lives”:

推进 ANI“服务患者，改善生活”的使命：

EMCITATE

addresses MCT8 deficiency, a devastating ultra-rare disease marked by severe lifelong morbidity and substantial caregiver burden, furthering ANI’s commitment to bringing innovative therapies to patients with significant unmet need.

针对MCT8缺乏症，这是一种破坏性的超罕见疾病，以严重的终身病痛和沉重的照护者负担为特征，进一步彰显了ANI致力于为满足重大未满足医疗需求的患者带来创新疗法的承诺。

Accelerates

加速

ANI’s strategic transformation into a leading Rare Disease company:

ANI战略转型为领先的罕见病公司：

The proposed transaction expands the scope and scale of ANI’s Rare Disease business by broadening the Company’s commercial footprint and adding EMCITATE

拟议的交易通过扩大公司的商业版图并纳入EMCITATE，拓展了ANI罕见病业务的范围和规模。

, a commercial product with over $300 million in peak sales potential in its approved indication.

，这是一款商业产品，在其获批适应症中的峰值销售潜力超过3亿美元。

Introduces a new growth driver with durable runway into 2045:

引入一个具有持久增长空间直至2045年的新增长引擎：

As the first and only FDA-approved treatment of peripheral thyrotoxicosis associated with MCT8 deficiency, EMCITATE

作为首个且唯一获美国食品药品监督管理局（FDA）批准用于治疗与MCT8缺乏症相关的外周甲状腺毒症的药物，EMCITATE

has significant growth potential that ANI plans to unlock with its resources, commercial capabilities, and infrastructure. EMCITATE

具有巨大的增长潜力，ANI计划利用其资源、商业能力和基础设施来释放这一潜力。EMCITATE

’s durability is supported by New Chemical Entity exclusivity, Orphan Drug exclusivity in both the U.S. and Europe, and an Orange Book-listed patent offering protection into mid-2045.

其持久性得益于新化学实体独占权、美国和欧洲的孤儿药独占权，以及列入橙皮书的专利所提供的保护（有效期至2045年中期）。

Leverages ANI’s resources and existing Rare Disease expertise and infrastructure:

利用ANI的资源以及现有的罕见病专业知识和基础设施：

ANI intends to build on Egetis’ U.S. commercial launch preparations by leveraging its resources, extensive experience in Rare Disease, and existing medical affairs, patient access and reimbursement support.

ANI 旨在通过利用其资源、在罕见病领域的丰富经验，以及现有的医学事务、患者准入和报销支持，来推进 Egetis 在美国的商业化发布准备工作。

Strengthens ANI’s clinical development capabilities:

增强ANI的临床开发能力：

The proposed transaction adds a proven research and development team with an ongoing clinical program to evaluate tiratricol in resistance to thyroid hormone beta (RTH-beta).

拟议的交易增加了一支经验丰富的研发团队，该团队正在进行一项临床试验项目，以评估替拉曲可（tiratricol）在治疗甲状腺激素β受体抵抗症（RTH-beta）中的疗效。

Diversifies ANI’s revenue base and enhances its long-term growth and profitability profile.

多元化ANI的收入基础，并提升其长期增长和盈利能力。

Transaction Details

交易详情

On November 5, 2026, ANI announced a recommended public offer to acquire the shares in Egetis for SEK 11.25 per share, representing a 27% premium to the 60-day VWAP, as well as the convertible debt and the warrants issued by Egetis. The value of the Offer, including outstanding incentive programs, amounts to approximately SEK 5.6 billion or approximately $560.

2026年11月5日，ANI宣布一项建议性公开要约，以每股11.25瑞典克朗的价格收购Egetis的股份，该价格较60日成交量加权平均价（VWAP）溢价27%，同时收购Egetis发行的可转换债务及认股权证。包括未行权的激励计划在内，本次要约的价值约为56亿瑞典克朗（约合5.6亿美元）。

million. On November 4, 2026, Egetis announced that it had entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $190.0 million (USD). Upon the closing of the PRV sale, former owners of Rare Thyroid Therapeutics International AB (RTTI) will receive an earn-out of their share under agreements governing Egetis’ acquisition of RTTI.

百万美元。2026年11月4日，Egetis宣布已签订一项具有约束力的资产购买协议，将其罕见儿科疾病优先审评券（PRV）出售，总收益为1.9亿美元（美元）。在PRV出售交易完成后，Rare Thyroid Therapeutics International AB（RTTI）的前所有者将根据管辖Egetis收购RTTI的相关协议，获得其应得的或有对价。

The consideration in the Offer fully reflects the net value of the PRV on the terms of that sale. When adjusted for the estimated PRV net proceeds, the enterprise value reflected in the deal is approximately $434.

要约对价充分反映了该销售条款下PRV的净值。经估计的PRV净收益调整后，该交易反映的企业价值约为434美元。

million.

百万。

The Board of Directors of Egetis unanimously recommends that Egetis’ shareholders and the holder of the convertible and the warrants accept the Offer. In addition, shareholders representing in total approximately 42 percent of the total number of outstanding shares in Egetis, have undertaken to accept the Offer, under certain conditions..

Egetis董事会一致建议Egetis的股东以及可转换债券和认股权证的持有人接受该要约。此外，代表Egetis已发行股份总数约42%的股东已在某些条件下承诺接受该要约。

The Offer is subject to customary closing conditions, including that the Offer is accepted by shareholders representing at least 90 percent of the outstanding shares in Egetis, and that ANI receives necessary regulatory approvals.

该要约须满足惯例交割条件，包括获得代表Egetis至少90%已发行股份的股东接受，以及ANI获得必要的监管批准。

The Offer is financed in full through a combination of cash on hand and new debt financing provided by JPMorgan Chase Bank, N.A., on terms customary for financing of public offers on the Swedish market.

本次要约的资金全部通过手头现金以及由摩根大通银行（JPMorgan Chase Bank, N.A.）提供的新债务融资相结合的方式筹集，融资条款符合瑞典市场公开要约融资的惯例。

The acceptance period in the offer is expected to commence on or around November 20, 2026 and to expire on or around December 18, 2026. For information in relation to the Offer, please refer to the formal offer announcement available on

要约的接受期预计将于2026年11月20日左右开始，并于2026年12月18日左右届满。有关要约的信息，请参阅发布于

www.biopharma-offer.com

。

Advisors

顾问

For ANI Pharmaceuticals, Jefferies LLC is serving as sole financial advisor and Ropes & Gray LLP and Mannheimer Swartling Advokatbyrå AB are serving as legal counsel. For Egetis Therapeutics, Centerview Partners is serving as sole financial advisor, and Vinge is serving as legal counsel.

就ANI Pharmaceuticals而言，Jefferies LLC担任独家财务顾问，Ropes & Gray LLP和Mannheimer Swartling Advokatbyrå AB担任法律顾问。就Egetis Therapeutics而言，Centerview Partners担任独家财务顾问，Vinge担任法律顾问。

Conference Call

电话会议

ANI will host a conference call and webcast today, Thursday, November 5, 2026, at 8:00 a.m. ET to discuss the acquisition and third quarter 2026 financial results.

ANI 将于今日，即2026年11月5日（星期四）美国东部时间上午8:00举行电话会议和网络直播，讨论此次收购及2026年第三季度财务业绩。

To join the conference call, please dial +1(833) 630-1956 (U.S. and Canada) or +1(412) 317-1837 (International callers).

如需加入电话会议，请拨打 +1(833) 630-1956（美国和加拿大）或 +1(412) 317-1837（国际呼叫者）。

To view the webcast and accompanying slides, please click

如需观看网络直播及随附幻灯片，请点击

here

这里

. Links to access the webcast will also be available on the “Events & Presentations” page of the Company’s website at

访问网络直播的链接也将可在公司网站的“活动与演示”页面获取，网址为

https://www.anipharmaceuticals.com

, under the “Investors” section. A replay of the event will remain accessible for up to one year.

，在“投资者”栏目下。活动回放将在一年内保持可访问。

About ANI Pharmaceuticals, Inc.

关于 ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business.

ANI Pharmaceuticals, Inc.（纳斯达克股票代码：ANIP）是一家多元化的生物制药公司，致力于通过开发、生产和商业化创新且高质量的治疗产品，践行其“服务患者，改善生活”的使命。公司专注于通过以下业务板块实现可持续增长：罕见病业务，在眼科、风湿病学、肾脏病学、神经病学和肺病学领域推广创新产品；仿制药业务，依托研发专长、卓越运营以及位于美国的生产设施；以及品牌药业务。

For more information, visit .

更多信息，请访问。

https://www.anipharmaceuticals.com

。

Forward-Looking Statements

前瞻性陈述

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the public offer to acquire Egetis; the Company’s strategy and ability to transform into a leading Rare Disease company; the Company’s expectations regarding its future operations; the commercialization and anticipated sales of EMCITATE.

在本新闻稿中，任何涉及非历史性信息的陈述均构成1995年《私人证券诉讼改革法案》意义上的前瞻性陈述。此类陈述包括但不限于：关于收购Egetis的公开要约的陈述；公司转型为领先罕见病公司的战略及能力；公司对其未来运营的预期；以及EMCITATE的商业化及预期销售情况。

注册商标符号

and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates..

以及其他非历史性质的陈述，特别是那些使用“预计”、“将”、“期望”、“计划”、“潜在”、“未来”、“相信”、“打算”、“继续”等术语、其否定形式、其他具有类似含义的词语、这些词语的派生词以及使用未来日期的陈述。

Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the Company’s ability to complete or achieve any or all of the intended benefits of the proposed acquisition of Egetis, in a timely manner or at all; regulatory approvals required for the transaction not being timely obtained, if obtained at all; the Egetis business experiencing disruptions due to transaction-related uncertainties or other factors; the Company being unable to successfully implement integration strategies; the ability of EMCITATE.

不确定性和风险可能导致公司的实际结果与前述前瞻性陈述中明示或暗示的结果存在重大差异。这些不确定性和风险包括但不限于：公司能否及时或完全完成拟议的Egetis收购并实现其全部或部分预期效益；交易所需的监管批准（如能获得）未能及时取得；因交易相关的不确定性或其他因素导致Egetis业务出现中断；公司无法成功实施整合策略；EMCITATE的能力。

and the Company’s approved products, including Cortrophin Gel and ILUVIEN, to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; the Company’s ability to develop, license or acquire, and commercialize new products; the Company’s ability to protect its intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and general business and economic conditions, such as inflationary pressures, and geopolitical conditions..

以及公司获批产品（包括Cortrophin Gel和ILUVIEN）实现商业化并达到足以维持公司盈利能力的市场接受度；美国食品药品监督管理局（FDA）、美国缉毒局（DEA）及其他监管机构可能采取的政策变化或行动；公司开发、许可或收购并商业化新产品的能力；公司保护其知识产权的能力；立法或监管改革对药品定价的影响；公司及其供应商、开发合作伙伴和生产合作伙伴遵守管辖或影响制药和生物技术行业的法律、法规和标准的能力；以及总体商业和经济状况，例如通货膨胀压力和地缘政治局势。

More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC.

有关这些及其他可能影响公司实际业绩的因素的更详细信息，请参阅公司向美国证券交易委员会（SEC）提交的文件，包括其最新的10-K表格年度报告和10-Q表格季度报告以及其他定期报告，以及向SEC提交的其他文件。

All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise..

本新闻稿中的所有前瞻性陈述仅反映本新闻稿发布之日的情况，并基于公司当前的信念、假设和预期。公司没有义务因新信息、未来事件或其他原因而更新或修订任何前瞻性陈述。

Important information to U.S. shareholders

致美国股东的重要信息

The Offer described in this press release is made for the shares, the convertible loan 2023:1 (the “Convertible”) and the warrants 2023/2033:1 (the “Warrants”) of Egetis, a Swedish public limited liability company, and is subject to Swedish disclosure and procedural requirements, which may be different from those of the United States.

本新闻稿所述的要约针对瑞典公众有限责任公司 Egetis 的股份、2023:1 可转换贷款（“可转换债券”）以及 2023/2033:1 认股权证（“认股权证”），并须遵守瑞典的信息披露及程序要求，这些要求可能与美国的要求不同。

The Offer is made in the United States pursuant to Section 14(e) of the U.S. Securities Exchange Act of 1934, as amended and Regulation 14E thereunder, to the extent applicable, and otherwise in compliance with the disclosure and procedural requirements of Swedish law, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered) and waivers of conditions, which may be different from requirements or customary practices in relation to U.S.

本要约依据经修订的《1934年美国证券交易法》第14(e)条及据此颁布的第14E号条例（在适用范围内）在美国作出，并在其他方面遵守瑞典法律关于披露和程序的要求，包括撤回权、要约时间表、延期通知、结果公告、结算程序（包括对价支付时间）以及条件豁免，这些要求可能与美国的要求或惯例不同。

domestic tender offers. Shareholders and the holder of the Convertible and the Warrants domiciled in the United States (the “U.S. Holders”) are encouraged to consult with their own advisors regarding the Offer..

境内要约收购。我们鼓励住所位于美国的股东及可转换证券和认股权证的持有人（“美国持有人”）就本次要约咨询其各自的顾问。

Egetis’ financial statements and all financial information included herein, or any other documents relating to the Offer, have been or will be prepared in accordance with IFRS and may not be comparable to the financial statements or financial information of companies in the United States or other companies whose financial statements are prepared in accordance with U.S.

Egetis 的财务报表及本文所包含的所有财务信息，或与本次要约相关的任何其他文件，均已或将根据《国际财务报告准则》（IFRS）编制，因此可能无法与美国公司或其他按照美国会计准则编制财务报表的公司的财务报表或财务信息进行直接比较。

generally accepted accounting principles. It may be difficult for Egetis’ shareholders and the holder of the Convertible and the Warrants to enforce their rights and any claims they may have arising under the U.S. federal or U.S. state securities laws in connection with the Offer, since Egetis is located in Sweden, and some or all of its officers and directors may be residents of countries other than the United States.

公认会计准则。由于Egetis位于瑞典，且其部分或全部高级管理人员和董事可能是美国以外国家的居民，因此Egetis的股东以及可转换证券和认股权证的持有人可能难以执行其与本次要约相关的、依据美国联邦或美国各州证券法所产生的权利及任何索赔。

Egetis’ shareholders and the holder of the Convertible and the Warrants may not be able to sue Egetis or its officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may be difficult to compel Egetis and its affiliates to subject themselves to the jurisdiction or judgment of a U.S.

Egetis 的股东以及可转换证券和认股权证的持有人可能无法在非美国法院就违反美国证券法的行为对 Egetis 或其高级管理人员或董事提起诉讼。此外，可能难以强制 Egetis 及其关联方接受美国法院的管辖权或判决。

court..

法院

To the extent permissible under applicable law or regulations, ANI and its affiliates or its brokers and its brokers' affiliates (acting as agents for ANI or its affiliates, as applicable) may from time to time and during the pendency of the Offer, and other than pursuant to the Offer, directly or indirectly purchase or arrange to purchase shares of Egetis outside the United States, or any securities that are convertible into, exchangeable for or exercisable for such shares.

在适用法律或法规允许的范围内，ANI 及其关联公司或其经纪人及其经纪人的关联公司（视情况作为 ANI 或其关联公司的代理人行事）可能不时且在要约有效期内，除依据本要约外，直接或间接购买或安排购买 Egetis 在美国境外的股份，或任何可转换为、可交换为或可行使为该等股份的证券。

These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices, and information about such purchases will be disclosed by means of a press release or other means reasonably calculated to inform U.S. Holders of such information, to the extent required by applicable laws and regulations.

此类购买可能以现行价格在公开市场进行，或以协商价格在私人交易中进行，并且关于此类购买的信息将通过新闻稿或其他合理旨在向美国持有人告知该信息的方式予以披露，但以适用法律法规要求的范围为限。

In addition, the financial advisors to ANI may also engage in ordinary course trading activities in securities of Egetis, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements comply with the applicable laws and regulations. Any information about such purchases will be announced in Swedish and in a non-prevailing English translation available to the U.S.

此外，ANI的财务顾问也可能参与Egetis证券的常规交易活动，包括购买或安排购买此类证券，只要此类购买或安排符合适用的法律法规。有关此类购买的任何信息将以瑞典语公布，并提供供美国使用的非权威英文译本。

Holders through relevant electronic media if, and to the extent, such announcement is required under applicable Swedish or U.S. law, rules or regulations..

通过相关电子媒体向持有人发布公告，且仅在适用的瑞典或美国法律、规则或法规要求的情况下及在此范围内进行。

The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each shareholder is urged to consult an independent professional adviser regarding the tax consequences of accepting the Offer.

美国持有人根据要约收取现金的行为，就美国联邦所得税以及适用的美国州和地方税法、外国及其他税法而言，可能构成应税交易。敦促每位股东就接受要约的税务后果咨询独立的专业顾问。

Neither ANI nor any of its affiliates and their respective directors, officers, employees or agents or any other person acting on their behalf in connection with the Offer shall be responsible for any tax effects or liabilities resulting from acceptance of this Offer..

ANI及其任何关联公司，以及它们各自的董事、高级管理人员、员工或代理人，或代表它们参与本次要约的任何其他人，均不对因接受本次要约而产生的任何税务影响或责任负责。

NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE OFFER, MADE ANY COMMENTS UPON THE MERITS OR FAIRNESS OF THE OFFER, MADE ANY COMMENT UPON THE ADEQUACY OR COMPLETENESS OF THIS PRESS RELEASE OR MADE ANY COMMENT ON WHETHER THE CONTENT IN THIS PRESS RELEASE IS CORRECT OR COMPLETE.

美国证券交易委员会及任何美国州证券委员会均未批准或不批准本次要约，未就本次要约的优点或公平性发表任何意见，未就本新闻稿的充分性或完整性发表任何意见，也未就本新闻稿内容的正确性或完整性发表任何意见。

ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES..

任何相反的陈述在美国均构成刑事犯罪。

For purposes of this section 'United States' and 'U.S.' means the United States of America (its territories and possessions, all states of the United States of America and the District of Columbia).

为本节之目的，“美国”和“U.S.”系指美利坚合众国（其领土和属地、美利坚合众国所有州以及哥伦比亚特区）。

Information about the Offer

关于要约的信息

Information regarding the Offer is made available at:

有关本次发行的信息可在以下网址获取：

www.biopharma-offer.com

。

ANI Pharmaceuticals Contacts

ANI 制药联系方式

Investor Relations:

投资者关系：

Irina Koffler, Vice President, Investor Relations